Second neoplasms after invasive and borderline ovarian cancer.
Excess risk of subsequent cancers has been documented in women diagnosed with ovarian cancer. We updated to 2006 data on second cancers in women diagnosed with invasive and borderline ovarian cancer in the Swiss canton of Vaud. Between 1974 and 2006, 304 borderline and 1530 invasive first ovarian tumours were abstracted from the Vaud Cancer Registry database and followed up till the end of 2006. Calculation of expected numbers of tumours in the cohorts was based on site-specific, age-specific and calendar-year-specific incidence rates. We computed the standardized incidence ratios (SIRs) of second cancers, and the corresponding 95% confidence intervals (CI). There was no change in the incidence of malignant cancers, but that of borderline tumours increased over more recent years. Overall, 110 second neoplasms were observed versus 49.7 expected after invasive ovarian cancer (SIR 2.21; 95% CI: 1.82-2.67). Significant excess risks were observed for cancers of the breast, corpus uteri and leukaemias. When synchronous cancers were excluded, the overall SIR for all sites declined to 1.05. Thirty-one second neoplasms were observed after borderline tumours compared with 21.1 expected (SIR=1.47; 95% CI: 1.00-2.09). SIRs were above unity for ovary, colorectum and uterus. After exclusion of synchronous neoplasms, SIR for all neoplasms declined to 1.09, and remained significant only for second ovarian cancers (SIR=4.93). The present record linkage cohort study shows an excess risk for selected synchronous neoplasms in women diagnosed with both borderline and invasive ovarian cancer, likely because of shared genetic and perhaps environmental factors.
Levi
Fabio
F
Cancer Epidemiology Unit and Cancer Registry of Vaud, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Vaud and University of Lausanne, Lausanne, Switzerland.
Randimbison
Lalao
L
Blanc-Moya
Rafael
R
La Vecchia
Carlo
C
D018262:Adenocarcinoma, Clear Cell / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000473:pathology; D018269:Carcinoma, Endometrioid / Q000473:pathology; D015331:Cohort Studies; D018284:Cystadenocarcinoma, Serous / Q000473:pathology; D016889:Endometrial Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000209:etiology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D012042:Registries